The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis

Adalimumab, Tacrolimus Effective for Treating Refractory Ulcerative Colitis

October 15, 2015 • By Will Boggs, MD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

NEW YORK (Reuters Health)—The human IgG1 anti-TNF antibody adalimumab is safe and effective for short- and long-term treatment, and the calcineurin inhibitor tacrolimus given short-term brings remission, in patients with refractory ulcerative colitis, according to two new studies in the Journal of Crohn’s and Colitis.

You Might Also Like
  • Rectosigmoidoscopy vs. Colonoscopy for Assessing Ulcerative Colitis Activity
  • Methotrexate for Ulcerative Colitis Yields Mixed Results
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis

In the first study, online Sept. 21, Dr. Tamas Molnar from University of Szeged in Hungary examined the short- and long-term efficacy and safety of adalimumab in every adalimumab-treated ulcerative colitis patient from each center in Hungary that uses the drug.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Of the 73 patients included in the report, 49 had been treated previously with infliximab. A third of the patients were on steroids and just over half (52%) were on immunosuppressants at baseline.

By week 12, 49.3% of patients experienced a clinical response, 26% achieved remission, and 24.7% remained unresponsive to induction treatment.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

By week 52, 45.2% of patients showed a continuous clinical response with adalimumab. Results did not differ according to prior treatment (or not) with infliximab.

“In the real-life setting, adalimumab is more efficacious than in the studies,” Dr. Molnar told Reuters Health by email. “Adalimumab can be optimal for chronic refractory, steroid-dependent ulcerative colitis. We have no data about the role of adalimumab in acute, steroid-refractory colitis.”

In a second study, online Sept. 29, Dr. Jurgen Buning from University Hospital of Schleswig-Holstein in Lubeck, Germany, and colleagues examined the long-term outcome of tacrolimus-treated steroid-refractory ulcerative colitis.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

The 156 patients included in their study received tacrolimus orally or intravenously daily for a median 5.3 months (range, 0.1–47.2 months). About half the patients (n=89) also received a purine analogue in the early course of tacrolimus, and 79 of 137 patients without colectomy or relapse by week 12 received purine analogue therapy thereafter.

Overall, colectomy was performed in 45 patients, including 18 within the first three months while receiving tacrolimus, five more by six months, five more before 12 months, seven more by 24 months, and 10 beyond 24 months.

Two-thirds of the patients achieved clinical remission which they maintained a median 0.9 years. Remission rates fell to 53.8% at 12 months and 39.7% at 24 months.

Colectomy rates did not differ significantly between patients treated with purine analogues and without purine analogues (18% vs. 22%; p=0.49).

Median times to colectomy, however, were significantly longer in patients who also received purine analogues (two years) than in those who did not receive purine analogues (0.8 year). Remission rates were also higher in patients treated with purine analogues (82% vs. 51% without purine analogues).

Pages: 1 2 | Single Page

Filed Under: Biologics & Biosimilars, Conditions, Drug Updates, Systemic Inflammatory Syndromes Tagged With: adalimumab, Anti-TNF, tacrolimus, ulcerative colitis

You Might Also Like:
  • Rectosigmoidoscopy vs. Colonoscopy for Assessing Ulcerative Colitis Activity
  • Methotrexate for Ulcerative Colitis Yields Mixed Results
  • Golimumab Effective as Maintenance Treatment for Active Ulcerative Colitis
  • Pricey Arthritis Drug Effective in Small Fraction of Ulcerative Colitis Cases

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.